FDA

Scholar argues that FDA should adopt an evidenced-based approach to regulating drug manufacturers’ speech.

Scholar argues for greater privacy protections of personal medical data collected by wearable health technologies.

Scholar argues that FDA should be the sole regulator of cell-cultured meat.

FDA approves first over-the-counter treatment to combat the opioid overdose epidemic.

Existing patents deter the marketing of more affordable generic drugs that could be used off-label for abortions.

Businesses in the United States are increasingly supporting regulation and regulators against judicial decisions curtailing agency authority.

Recent abortion pill litigation underscores the significance of calls to make birth control pills available over the counter.

Scholar argues that loopholes in U.S. food regulation put consumers at risk.

Scholar calls for FDA to remove stringent restrictions on medication abortion.

Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.

Scholar argues that Congress and FDA should treat risky clinical artificial intelligence tools as medical devices.

FDA’s approach to evidence-based decision-making may not be addressed to the right people.